BLTE Live signaler | Maksimer profitt med Getagraph.com

KJøP 101593 min ago

@ $47.00

Utstedt: 13 feb 2024 @ 15:30

Avkastning: -21.28%

Forrige signal: feb 9 - 15:43

Forrige signal: Selg

Avkastning: 0.90 %

Live Chart Being Loaded With Signals

Commentary (23 apr 2024 @ 22:00):

Stats
Dagens volum	38 820.00
Gjennomsnittsvolum	50 908.00
Markedsverdi	1.10B
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-31.09
ATR14	$0.0910 (0.24%)

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: 0.28 (neutral)

Signal:(66.043) Neutral

Belite Bio, Inc Korrelasjon

10 Mest positive korrelasjoner
VLCN	0.958
HIBB	0.957
IART	0.953
JRJC	0.945
VBFC	0.935
EMKR	0.935
IEP	0.934
IVAC	0.929
MLAB	0.926
GOGL	0.924

10 Mest negative korrelasjoner
SMCI	-0.957
OPRA	-0.953
VIRI	-0.951
NVDA	-0.949
HGBL	-0.949
TZPS	-0.944
RXST	-0.943
AIB	-0.942
FRBN	-0.941
MLAI	-0.938

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Belite Bio, Inc Korrelasjon - Valuta/Råvare

0.60
( weak )

0.50
( weak )

0.00
( neutral )

0.60
( weak )

0.29
( neutral )

0.43
( neutral )

Belite Bio, Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-399 000 (0.00 %)
EPS:	$-1.190

Q4	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.250

Q3	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.400

Q2	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Belite Bio, Inc

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.